人类心脏衰竭的表观遗传疗法
Steven Leon1, Chia-Feng Liu2, W H Wilson Tang3
1Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA.
Heart failure clinics
|November 20, 2025
概括
表观遗传学在心力衰竭 (HF) 的发展中起着至关重要的作用. 新型表观遗传药物正在成为治疗这种广泛的心血管疾病的有希望的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一种全球性健康负担,影响心脏缩和/或放缩功能.
- 升的HF患病率需要创新的治疗策略.
- 表观遗传机制越来越多地被认为是HF的病原体.
研究的目的:
- 审查用于HF治疗的新兴表观遗传药物.
- 突出新型表观遗传药物的治疗潜力.
主要方法:
- 对HF的表观遗传疗法的当前临床发展的文献综述.
- 从临床前和临床研究中得出的关键发现的摘要.
主要成果:
- 几种表观遗传修饰与高频率有关.
- 针对这些修饰的表观遗传药物在早期发育中显示出有前途.
- 这种新的药物类别为HF管理提供了新的途径.
结论:
- 表观遗传失调是HF的一个重要因素.
- 向表观遗传机制代表了对HF的有希望的治疗前沿.
- 进一步的研究和临床试验对于验证这些新型治疗方法至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
Heart Failure VI: Adjunct Therapies
239
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
239
Heart Failure Drugs: Diuretics
775
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
775


